These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 24225420)

  • 21. On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.
    Daniëls V; Baekelandt V; Taymans JM
    Neurosignals; 2011; 19(1):1-15. PubMed ID: 21430363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Cell Biology of LRRK2 in Parkinson's Disease.
    Usmani A; Shavarebi F; Hiniker A
    Mol Cell Biol; 2021 Apr; 41(5):. PubMed ID: 33526455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The neurobiology of LRRK2 and its role in the pathogenesis of Parkinson's disease.
    Rideout HJ; Stefanis L
    Neurochem Res; 2014; 39(3):576-92. PubMed ID: 23729298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LRRK2 links genetic and sporadic Parkinson's disease.
    Kluss JH; Mamais A; Cookson MR
    Biochem Soc Trans; 2019 Apr; 47(2):651-661. PubMed ID: 30837320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.
    Plowey ED; Cherra SJ; Liu YJ; Chu CT
    J Neurochem; 2008 May; 105(3):1048-56. PubMed ID: 18182054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An emerging role for LRRK2 in the immune system.
    Dzamko N; Halliday GM
    Biochem Soc Trans; 2012 Oct; 40(5):1134-9. PubMed ID: 22988878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LRRK2 and autophagy: a common pathway for disease.
    Manzoni C
    Biochem Soc Trans; 2012 Oct; 40(5):1147-51. PubMed ID: 22988880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical molecular genetics for PARK8 (LRRK2)].
    Tomiyama H; Hatano T; Hattori N
    Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
    Greggio E
    Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways.
    Sancho RM; Law BM; Harvey K
    Hum Mol Genet; 2009 Oct; 18(20):3955-68. PubMed ID: 19625296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player.
    Häbig K; Walter M; Poths S; Riess O; Bonin M
    Neurogenetics; 2008 May; 9(2):83-94. PubMed ID: 18097693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review.
    Chen ML; Wu RM
    J Biomed Sci; 2018 Jun; 25(1):52. PubMed ID: 29903014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm.
    Esteves AR; G-Fernandes M; Santos D; Januário C; Cardoso SM
    Mol Neurobiol; 2015 Dec; 52(3):1804-1820. PubMed ID: 25394383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The biology and pathobiology of LRRK2: implications for Parkinson's disease.
    Moore DJ
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S92-8. PubMed ID: 18602856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.
    Brockmann K; Gröger A; Di Santo A; Liepelt I; Schulte C; Klose U; Maetzler W; Hauser AK; Hilker R; Gomez-Mancilla B; Berg D; Gasser T
    Mov Disord; 2011 Nov; 26(13):2335-42. PubMed ID: 21989859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions.
    Drolet RE; Sanders JM; Kern JT
    J Neurogenet; 2011 Dec; 25(4):140-51. PubMed ID: 22077787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What genetics tells us about the causes and mechanisms of Parkinson's disease.
    Corti O; Lesage S; Brice A
    Physiol Rev; 2011 Oct; 91(4):1161-218. PubMed ID: 22013209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.
    Greggio E; Jain S; Kingsbury A; Bandopadhyay R; Lewis P; Kaganovich A; van der Brug MP; Beilina A; Blackinton J; Thomas KJ; Ahmad R; Miller DW; Kesavapany S; Singleton A; Lees A; Harvey RJ; Harvey K; Cookson MR
    Neurobiol Dis; 2006 Aug; 23(2):329-41. PubMed ID: 16750377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.
    Cho HJ; Liu G; Jin SM; Parisiadou L; Xie C; Yu J; Sun L; Ma B; Ding J; Vancraenenbroeck R; Lobbestael E; Baekelandt V; Taymans JM; He P; Troncoso JC; Shen Y; Cai H
    Hum Mol Genet; 2013 Feb; 22(3):608-20. PubMed ID: 23125283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A link between LRRK2, autophagy and NAADP-mediated endolysosomal calcium signalling.
    Gómez-Suaga P; Churchill GC; Patel S; Hilfiker S
    Biochem Soc Trans; 2012 Oct; 40(5):1140-6. PubMed ID: 22988879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.